The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Carrier effects on biological activity of amphotericin B
Open accessAbstract
Amphotericin B (AmB), the drug of choice for the treatment of most systemic fungal infections, is marketed under the trademark Fungizone, as an AmB-deoxycholate complex suitable for intravenous administration. The association between AmB and deoxycholate is relatively weak; therefore, dissociation occurs in the blood. The drug itself interacts with both mammalian and fungal cell membranes to damage cells, but the greater susceptibility of fungal cells to its effects forms the basis for its clinical usefulness. The ability of the drug to form stable complexes with lipids has allowed the development of new formulations of AmB based on this property. Several lipid-based formulations of the drug which are more selective in damaging fungal or parasitic cells than mammalian cells and some of which also have a better therapeutic index than Fungizone have been developed. In vitro investigations have led to the conclusion that the increase in selectivity observed is due to the selective transfer of AmB from lipid complexes to fungal cells or to the higher thermodynamic stability of lipid formulations. Association with lipids modulates AmB binding to lipoproteins in vivo, thus influencing tissue distribution and toxicity. For example, lipid complexes of AmB can be internalized by macrophages, and the macrophages then serve as a reservoir for the drug. Furthermore, stable AmB-lipid complexes are much less toxic to the host than Fungizone and can therefore be administered in higher doses. Experimentally, the efficacy of AmB-lipid formulations compared with Fungizone depends on the animal model used. Improved therapeutic indices for AmB-lipid formations have been demonstrated in clinical trials, but the definitive trials leading to the selection of an optimal formulation and therapeutic regimen have not been done.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
How do the polyene macrolide antibiotics affect the cellular membrane properties?
Bolard, J. (1986) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(86)90002-x · Cited by 750
Self-citationAmphotericin B: current understanding of mechanisms of action
Brajtburg, J., Powderly, W. G., Kobayashi, G. S., & Medoff, G. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.2.183 · Cited by 504
Self-citationRecent Trends in the Discovery, Development, and Evaluation of Antifungal Agents
Fromtling, R. A., Braun, P. C., & Hector, R. (1987) · DigitalCommons - Fairfield (Fairfield University) · Cited by 474
Lopez-Berestein, G., Fainstein, V., Hopfer, R., Mehta, K., Sullivan, M. P., Keating, M., Rosenblum, M. G., Mehta, R., Luna, M., Hersh, E. M., et al. (1985) · Journal of Infectious Diseases · doi:10.1093/infdis/151.4.704 · Cited by 405
Lopez-Berestein, G., Mehta, R., Hopfer, R. L., Mills, K., Kasi, L., Mehta, K., Fainstein, V., Luna, M., Hersh, E. M., & Juliano, R. (1983) · Journal of Infectious Diseases · doi:10.1093/infdis/147.5.939 · Cited by 303
Liposomal and Lipid Formulations of Amphotericin B: Clinical Pharmacokinetics
Janknegt, R., de Marie, S., Bakker-Woudenberg, I. A. J. M., & Crommelin, D. J. A. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223040-00004 · Cited by 274
Bolard, J., Legrand, P., Heitz, F., & Cybulska, B. (1991) · Biochemistry · doi:10.1021/bi00237a011 · Cited by 268
Self-citationAdler-moore, J. P., & Proffitt, R. T. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150729 · Cited by 251
Amphotericin B-resistant yeast infection in severely immunocompromised patients
Powderly, W. G., Kobayashi, G. S., Herzig, G. P., & Medoff, G. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90059-9 · Cited by 232
Distribution and Activity of Amphotericin B in Humans
Christiansen, K. J., Bernard, E. M., Gold, J. W. M., & Armstrong, D. (1985) · Journal of Infectious Diseases · doi:10.1093/infdis/152.5.1037 · Cited by 229
Unusual lipid structures selectively reduce the toxicity of amphotericin B.
Janoff, A. S., Boni, L. T., Popescu, M. C., Minchey, S. R., Cullis, P. R., Madden, T. D., Taraschi, T., Gruner, S. M., Shyamsunder, E., & Tate, M. W. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.6122 · Cited by 223
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
Lopez-Berestein, G., Bodey, G. P., Frankel, L. S., & Mehta, K. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.2.310 · Cited by 216
Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents
Proffitt, R. T., Satorius, A., Chiang, S.-M., Sullivan, L., & Adler-Moore, J. P. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.49 · Cited by 203
Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes
Legrand, P., Romero, E. A., Cohen, B. E., & Bolard, J. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.11.2518 · Cited by 201
Self-citationTreatment of Murine Cryptococcosis with Liposome-Associated Amphotericin B
Graybill, J. R., Craven, P. C., Taylor, R. L., Williams, D. M., & Magee, W. E. (1982) · Journal of Infectious Diseases · doi:10.1093/infdis/145.2.748 · Cited by 201
Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial
(1994) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068903 · Cited by 195
Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells
Mehta, R., Lopez-Berestein, G., Hopfer, R., Mills, K., & Juliano, R. L. (1984) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(84)90135-4 · Cited by 192
Francis, P., Lee, J. W., Hoffman, A., Peter, J., Francesconi, A., Bacher, J., Shelhamer, J., Pizzo, P. A., & Walsh, T. J. (1994) · Journal of Infectious Diseases · doi:10.1093/infdis/169.2.356 · Cited by 185
Szoka, F. C., Milholland, D., & Barza, M. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.3.421 · Cited by 177
Treatment of systemic fungal infections with liposomal amphotericin B.
Lopez-Berestein, G., Bodey, G. P., Fainstein, V., Keating, M. J., Frankel, L. S., Zeluff, B. J., Gentry, L. K., & Mehta, K. (1989) · PubMed · Cited by 176
Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes
New, R. R. C., Chance, M. L., & Heath, S. (1981) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/8.5.371 · Cited by 176
Potassium fluxes, first indications of membrane damage in micro-organisms
Lambert, P. A., & Hammond, S. M. (1973) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(73)91494-0 · Cited by 163
Amphotericin B lipid complex therapy of experimental fungal infections in mice
Clark, J. M., Whitney, R. R., Olsen, S. J., George, R. J., Swerdel, M. R., Kunselman, L., & Bonner, D. P. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.4.615 · Cited by 159
Amphotericin B in Liposomes: A Novel Therapy for Histoplasmosis
Taylor, R. L., Williams, D. M., Craven, P. C., Graybill, J. R., Drutz, D. J., & Magee, W. E. (1982) · American Review of Respiratory Disease · doi:10.1164/arrd.1982.125.5.610 · Cited by 156
Mode of Action of Clinically Important Antifungal Drugs
Kerridge, D. (1986) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/s0065-2911(08)60303-3 · Cited by 143
Lee, J. W., Amantea, M., Francis, P. A., Navarro, E. E., Bacher, J. D., Pizzo, P. A., & Walsh, T. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.713 · Cited by 134
Clinical use of liposomal and lipid-complexed amphotericin B
de Marie, S., Janknegt, R., & Bakker‐Woudenberg, I. A. J. M. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.5.907 · Cited by 133
Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host
Denning, D. W. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.1 · Cited by 126
Liposome-Encapsulated Amphotericin B for Treatment of Disseminated Candidiasis in Neutropenic Mice
Lopez‐Berestein, G., Hopfer, R. L., Mehta, R. T., Mehta, K., Hersh, E. M., & Juliano, R. L. (1984) · The Journal of Infectious Diseases · doi:10.1093/infdis/150.2.278 · Cited by 125
Janoff, A. S., Perkins, W. R., Saletan, S., & Swenson, C. E. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150730 · Cited by 122
Moreau, P., Milpied, N. J., Fayette, N., Ramée, J., & Harousseau, J. (1992) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/30.4.535 · Cited by 118
Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.
Juliano, R. L., Grant, C. W. M., Barber, K. R., & Kalp, M. A. (1987) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10311-8 · Cited by 118
Fielding, R. M., Smith, P. C., Wang, L. H., Porter, J., & Guo, L. S. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.6.1208 · Cited by 117
Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B
Brajtburg, J., Elberg, S., Schwartz, D. R., Vertut‐Doï, A., Schlessinger, D., Kobayashi, G. S., & Medoff, G. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.27.2.172 · Cited by 114
Self-citationFielding, R. M., Singer, A. W., Wang, L. H., Babbar, S., & Guo, L. S. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.2.299 · Cited by 110
Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs
Guo, L. S. S., Fielding, R. M., Lasiç, D. D., Hamilton, R. L., & Mufson, D. (1991) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(91)90249-n · Cited by 110
Allen, S. D., Sorensen, K. N., Neial, M. J., Durrant, C., & Proffitt, R. T. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/34.6.1001 · Cited by 105
Kirsh, R. L., Goldstein, R., Tarloff, J. B., Parris, D., Hook, J., Hanna, N., Bugelski, P. J., & Poste, G. H. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.5.1065 · Cited by 103
Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B
Anaissie, E. J., Paetznick, V. L., Proffitt, R. T., Adler‐Moore, J., & Bodey, G. P. (1991) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01975823 · Cited by 102
Collette, N., van der Auwera, P., Lopez, A. P., Heymans, C., & Meunier, F. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.3.362 · Cited by 102
Liposomes as carriers of antimicrobial agents
Lopez‐Berestein, G. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.5.675 · Cited by 101
Gondal, J. A., Swartz, R. P., & Rahman, A. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.9.1544 · Cited by 101
Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice
Tremblay, C., Barza, M. J., Fiore, C., & Szoka, F. C. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.26.2.170 · Cited by 97
Liposomal amphotericin B, AmBisome
Hay, R. J. (1994) · Journal of Infection · doi:10.1016/s0163-4453(94)95956-0 · Cited by 97
VYVODA, O. S., COLEMAN, R., & Holdsworth, G. (1977) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(77)90356-x · Cited by 93
Kan, V. L., Bennett, J. E., Amantea, M., Smolskis, M. C., McManus, E., Grasela, D. M., & Sherman, J. W. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.2.418 · Cited by 93
Patterson, T. F., Miniter, P., Dijkstra, J., Szoka, F. C., Ryan, J. L., & Andriole, V. T. (1989) · The Journal of Infectious Diseases · doi:10.1093/infdis/159.4.717 · Cited by 93
Wasan, K. M., Brazeau, G. A., Keyhani, A., Hayman, A. C., & Lopez‐Berestein, G. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.2.246 · Cited by 90
In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B
Hopfer, R. L., Mills, K., Mehta, R. T., Lopez‐Berestein, G., Fainstein, V., & Juliano, R. L. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.3.387 · Cited by 89
Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity
Perkins, W. R., Minchey, S. R., Boni, L. T., Swenson, C. E., Popescu, M. C., Pasternack, R. F., & Janoff, A. S. (1992) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(92)90414-h · Cited by 87
Cohen, B. E. (1992) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(92)90113-z · Cited by 86
Wasan, K. M., Morton, R. E., Rosenblum, M. G., & Lopez‐Berestein, G. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600830716 · Cited by 82
Adler‐Moore, J., Chiang, S.-M., Satorius, A., Guerra, D., McAndrews, B., McManus, E. J., & Proffitt, R. T. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.63 · Cited by 81
The effect of surfactants on the aggregation state of amphotericin B
Tancrède, P., Barwicz, J., Jutras, S., & Gruda, I. (1990) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(90)90305-8 · Cited by 80
Sanders, S. W., Buchi, K. N., Goddard, M. S., Lang, J. K., & Tolman, K. G. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.6.1029 · Cited by 80
Amphotericin B revisited: reassessment of toxicity.
Js, C., & Peacock, J. E. (1990) · PubMed · Cited by 80
Tissue Distribution of Amphotericin B Lipid Complex in Laboratory Animals
Olsen, S., Swerdel, M. R., Blue, B., Clark, J. M., & BONNER, D. P. (1991) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1991.tb03189.x · Cited by 79
Caillot, D., Casasnovas, O., Solary, É., et al. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/31.1.161 · Cited by 78
Wasan, K. M., Vadiei, K., Lopez‐Berestein, G., & Luke, D. R. (1990) · The Journal of Infectious Diseases · doi:10.1093/infdis/161.3.562 · Cited by 76
How does Amphotericin B Work?: Studies on Model Membrane Systems
Hartsel, S. C., Hatch, C., & Ayenew, W. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150727 · Cited by 76
van Etten, E. W. M., Groot, C. V. D. H.-D., & Bakker‐Woudenberg, I. A. J. M. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/32.5.723 · Cited by 71
Hanson, L. H., & Stevens, D. A. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.2.486 · Cited by 70
Allende, M. C., Lee, J. W., Francis, P., Garrett, K. F., Dollenberg, H., Berenguer, J., Lyman, C. A., Pizzo, P. A., & Walsh, T. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.518 · Cited by 70
Amphotericin B and its delivery by liposomal and lipid formulations
Gates, C., & Pinney, R. J. (1993) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.1993.tb00605.x · Cited by 70
Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin.
Ringdén, O. T. H., Andström, E. E., Remberger, M., Svahn, B.-M., & Tollemar, J. G. (1994) · PubMed · Cited by 68
The effects of azole and polyene antifungals on the plasma membrane enzymes ofCandida albicans
Surarit, R., & Shepherd, M. G. (1987) · Medical Mycology · doi:10.1080/02681218780000491 · Cited by 67
Liposomes: Realizing Their Promise
Bangham, A. D. (1992) · Hospital Practice · doi:10.1080/21548331.1992.11705537 · Cited by 66
van Etten, E. W. M., ten Kate, M. T., Stearne, L. E. T., & Bakker‐Woudenberg, I. A. J. M. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.9.1954 · Cited by 65
Effects of Sterols on the Therapeutic Efficacy of Liposomal Amphotericin B in Murine Candidiasis
Lopez‐Berestein, G., Mehta, R. T., Hopfer, R. L., Mehta, K., Hersh, E. M., & Juliano, R. L. (1983) · Cancer Drug Delivery · doi:10.1089/cdd.1983.1.37 · Cited by 65
Pfaller, M. A., Bale, M. J., Buschelman, B. J., Lancaster, M., Espinel-Ingroff, A. V., Rex, J. H., & Rinaldi, M. G. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.7.1650-1653.1994 · Cited by 59
Hostetler, J. S., Clemons, K. V., Hanson, L. H., & Stevens, D. A. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2656 · Cited by 59
Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients
Collette, N., der Auwera, P. V., Meunier, F., Lambert, C., Sculier, J., & Coune, A. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/27.4.535 · Cited by 58
Clemons, K. V., & Stevens, D. A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.9.1829 · Cited by 57
Wang, L. H., Fielding, R. M., Smith, P. C., & Guo, L. S. S. (1995) · Pharmaceutical Research · doi:10.1023/a:1016243313027 · Cited by 55
Pahls, S., & Schaffner, A. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.5.1057 · Cited by 55
In vitro models for studying toxicity of antifungal agents
Joly, V., Bolard, J., & Yéni, P. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.9.1799 · Cited by 53
Self-citationCohen, B. E. (1986) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(86)90104-5 · Cited by 52
Perfect, J. R., & Wright, K. A. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.1.73 · Cited by 51
The endocytic process in CHO cells, a toxic pathway of the polyene antibiotic amphotericin B
Vertut‐Doï, A., Ohnishi, S., & Bolard, J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.10.2373 · Cited by 49
Self-citationMechanism of Action of Amphotericin B at the Cellular Level. Its Modulation by Delivery Systems
Bolard, J., Joly, V., & Yéni, P. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150728 · Cited by 46
Self-citationRalph, E. D., Khazindar, A. M., Barber, K. R., & Grant, C. W. M. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.1.188 · Cited by 45
Clemons, K. V., & Stevens, D. A. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/32.3.465 · Cited by 42
Payne, N. I., Cosgrove, R. F., Green, A. P., et al. (1987) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1987.tb07156.x · Cited by 42
The polyene antibiotic amphotericin B acts as a Ca2+ ionophore in sterol-containing liposomes
Ramos, H., Murciano, A., Cohen, B. E., & Bolard, J. (1989) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(89)90069-2 · Cited by 40
Self-citationClemons, K. V., & Stevens, D. A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.10.2144 · Cited by 40
Effect of Aggregation on the Kinetics of Autoxidation of the Polyene Antibiotic Amphotericin B
Lamy, M. T., Ferreira, V. F. N., Adelaide, F.-A., & Schreier, S. (1993) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600820209 · Cited by 39
Treatment of experimental murine candidiasis with liposome-associated amphotericin B
Ahrens, J., Graybill, J. R., Craven, P. C., et al. (1984) · Medical Mycology · doi:10.1080/00362178485380251 · Cited by 38
Liposomal amphotericin B therapy of murine histoplasmosis
Graybill, J. R., & Bocanegra, R. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.8.1885 · Cited by 37
Phagocyte Transport as Mechanism for Enhanced Therapeutic Activity of Liposomal Amphotericin B
Mehta, R. T., McQueen, T. J., Keyhani, A., & Lopez‐Berestein, G. (2009) · Chemotherapy · doi:10.1159/000239202 · Cited by 34
Joly, V., Bolard, J., Saint-Julien, L., Carbon, C., & Yéni, P. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.2.262 · Cited by 34
Self-citationClemons, K. V., & Stevans, D. A. (1992) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/30.3.353 · Cited by 33
Is there a correlation between serum antifungal drug concentration and clinical outcome?
Graybill, J. R. (1994) · Journal of Infection · doi:10.1016/s0163-4453(94)95926-9 · Cited by 31
Madden, T. D., Janoff, A. S., & Cullis, P. R. (1990) · Chemistry and Physics of Lipids · doi:10.1016/0009-3084(90)90114-7 · Cited by 30
Brajtburg, J., Elberg, S., Kobayashi, G. S., & Bolard, J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.2.300 · Cited by 28
Self-citationKaryotakis, N. C., & Anaissie, E. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.11.2660 · Cited by 26
Saint-Julien, L., Joly, V., Séman, M., Carbon, C., & Yéni, P. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2722 · Cited by 25
Mitsutake, K., Kohno, S., Miyazaki, Y., Noda, T., Miyazaki, H., Miyazaki, T., Kaku, M., Koga, H., & Hara, K. (1994) · Mycopathologia · doi:10.1007/bf01104273 · Cited by 24
Gokhale, P. C., Barapatre, R., Advani, S. H., Kshirsagar, N. A., & Pandya, S. K. (1993) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01372718 · Cited by 24
Emminger, W., Graninger, W. B., Emminger-Schmidmeier, W., Zoubek, A., Pillwein, K., Susani, M., Wasserer, A., & Gadner, H. (1994) · Annals of Hematology · doi:10.1007/bf01695916 · Cited by 23
Physical biochemistry of a liposomal amphotericin B mixture used for patient treatment
Grant, C. W. M., Hamilton, K. S., Hamilton, K. D., & Barber, K. R. (1989) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(89)90336-2 · Cited by 23
Wasan, K. M., & Lopez‐Berestein, G. (1993) · PubMed · Cited by 23
Hopfer, R. L., Mehta, R. T., & Lopez‐Berestein, G. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.12.1978 · Cited by 19
Dromer, F., Barbet, J., Bolard, J., Charreire, J., & Yéni, P. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.11.2055 · Cited by 19
Self-citationLiposomal amphotericin B inhibits in vitro T-lymphocyte response to antigen
Boggs, J. M., Chang, N.-H., & Goundalkar, A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.5.879 · Cited by 18
Allendoerfer, R., Yates, R. R., Sun, S. H., & Graybill, J. R. (1992) · Medical Mycology · doi:10.1080/02681219280000491 · Cited by 17
The Influence of Myrj 59 on the Solubility, Toxicity and Activity of Amphotericin B
Tasset, C. T., Véronique Préat, A., & Roland, M. (1991) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1991.tb06693.x · Cited by 17
Mechanism of Action of an Anti-Candida Drug: Amphotericin B and Its Derivatives
Bolard, J. (1991) · Springer eBooks · doi:10.1007/978-3-642-75253-7_14 · Cited by 15
Self-citationSullivan, G. W., Carper, H. T., & Mandell, G. L. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.1.39 · Cited by 15
Sculier, J., Delcroix, C., Brassinne, C., Laduron, C., Hollaert, C., & Coune, A. (1989) · Journal of Liposome Research · doi:10.3109/08982108909035988 · Cited by 14
Liposomal amphotericin B treatment in a 9‐month‐old liver recipient
Tollemar, J. G., DURAJ, F. F., & Ericzon, B. G. (1990) · Mycoses · doi:10.1111/myc.1990.33.5.251 · Cited by 13
Moonis, M., Ahmad, I. N., & Bachhawat, B. K. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.3.571 · Cited by 12
Pisarik, L., Joly, V., Jullièn, S., Carbon, C., & Yéni, P. (1990) · The Journal of Infectious Diseases · doi:10.1093/infdis/161.5.1042 · Cited by 10
Modulation of Amphotericin B Activity by Associan with Mannose Ester
Rocheleau, H., Saint-Gennain, G., Barwicz, J., Gruda, I., & Thérien, H.-M. (1994) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923979409007102 · Cited by 6
Cited by
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307
Amphotericin B: side effects and toxicity
Laniado-Laborín, R., & Cabrales-Vargas, M. N. (2009) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2009.06.003 · Cited by 739
Targeted Delivery of Amphotericin B to Cells by Using Functionalized Carbon Nanotubes
Wu, W., Wieckowski, S., Pastorin, G., Benincasa, M., Klumpp, C., Briand, J., Gennaro, R., Prato, M., & Bianco, A. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200501613 · Cited by 644
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Cavassin, F. B., Baú-Carneiro, J. L., Vilas-Boas, R. R., & Queiroz-Telles, F. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00382-7 · Cited by 382
Metadata
- Authors
- Brajtburg, J., & Bolard, J.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 1996-10
- Volume
- 9
- Issue
- 4
- Pages
- 512-531
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2141025633
- Cited by
- 310
- References
- 114
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.